Investors in Biotech

Pureos Bioventures is a venture capital fund, which invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

Metaplanet is an early-stage investment firm making long-term bets on contrarians and leveraging the knowledge and network across sectors. We back mission-driven founders working on positively disruptive deep technologies.

Elige Capital is an investor specializing in capital transmission and development capital operations for growing SMEs, in minority or majority, for investment tickets between 1 and 4 million euros. A dual DNA: entrepreneurs and investors Elige is led by an independent team that manages two investment vehicles subscribed by private investors who are business leaders and leading institutional investors. A flexible investment strategy whose main criterion is based on the women and men at the head of the companies and their development projects.

PPRS Venture positions itself uniquely in the biotech sector as "The Strategic Partnering Organization," specializing in innovative projects for diagnostics and therapeutics in neuroscience and orphan diseases. Based in Colmar, Alsace, with a subsidiary in Boston, USA, they combine independence in project selection with a multidisciplinary team of 25 associates. This team drives research collaborations encompassing over 100 stakeholders, from CROs to public and private labs. PPRS integrates robust financial and scientific expertise to support projects, from proof of concept to translational medicine, emphasizing risk management and global impact in their strategic approach.

The Fund operates within the BRIdgeAlfa Programme, financing research projects undertaken by young and innovative enterprises. The financing provided by the Fund is of a mixed nature and includes a component of equity financing from the Fund's private investors and a component of grant financing from the National Centre for Research and Development. The Fund’s activities are undertaken in close cooperation with the National Centre for Research and Development, which has its representative on the Fund’s Investment Committee.

The Normandy Littoral Fund was established to harness the significant natural assets of Normandy's 640 km coastline and its pivotal role in the region's economy, particularly with nearly 50,000 jobs in the seafood sector, making Normandy the second-largest region in France in this domain. Recognizing these strengths and challenges, the fund aims to serve as an active financial partner to maritime stakeholders. Its team, composed of specialists rooted in the region, deeply understands the concerns of maritime professionals and is committed to long-term engagement to support their strategic planning and project implementation. The fund's focus spans the maritime, coastal, and river sectors, aiming to foster sustainable development and growth through strategic investments and tailored financial solutions that contribute to the economic and environmental prosperity of Normandy's maritime economy.

Augere Health Food Fund Sp. z o.o. (augereventure.pl) is a seed fund dedicated to commercializing innovative technologies and products in the food sector, supporting the development of innovative Polish companies promoting health initiatives. We are constantly looking for innovative solutions that we could support in their commercial implementation on the market (

At AdBio Partners, we focus on ground-breaking innovations in Life Sciences to address unmet medical and clinical needs, building the next generation of pioneering healthcare companies. Keeping in mind patients’ well-being, our mission is to improve medical care and advance medical innovations. We collaborate closely with leading research institutions and well-established technology transfer offices, leveraging our strong network of scientific and medical partners to explore new territories, source breakthrough medical discoveries, and drive inventive Life Sciences start-ups to success.

JR HOLDING is an Alternative Joint-Stock Company listed on the NewConnect Exchange Market in Poland since 2012.In accordance with our strategy, we invest in several key sectors of the future, such as renewable sources of energy, gaming, lifestyle, artificial intelligence, new media or biotech. While creating a business, we believe in more than just good projects or sectors of big potential - we believe in people and realtions.

We invest in European early stage biotech opportunities with a clear path to the clinic, whether single-asset or platform. FORTY51 Ventures is the first institutional investor in your biotech company. FORTY51 Ventures Is A Biotech Venture Creator Company Building. We invest in European early stage biotech opportunities with a clear path to the clinic, whether single-asset or platform.

KOOPEO Ventures is Prague-based investment company that makes pre-seed and seed stage investments in CEE region.They seek out emerging projects with high growth potential in industries such as E-commerce, Mobile, Internet, Affiliate Marketing, and Fintech.

Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world's most urgent medical needs. Ω is the last letter of the Greek alphabet. Our investment process starts by focusing on the end goal – delivering impactful medicines to patients. We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others. Early seed or late stage public financing. Large markets or rare diseases. Established targets or novel technologies.